drugset / Trial / NCT00347425
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
Phase 3
Completed
286 enrolled
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | — | — |
| Subject | Olanzapine | Small molecule | — | — |
| Subject | Quetiapine | Small molecule | — | — |
| Subject | Risperidone | Other / unclassified | — | — |
| Subject | Ziprasidone | Small molecule | — | — |